News

As Seen In
RepliCel – Stem Cell Therapies Using Your Own Cells
To listen to Podcast and View Transcript on Future Tech Podcast, click here
As Seen In
Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis (ReaCT)
To read the full study as it appears on ClinicalTrials.gov, click here. Source: Clinical Trials....
Press Release
Positive Results from RepliCel’s RCS-01 Phase I Skin Trial are the Company’s Most Compelling to Date
Interim trial results lead researchers to conclude that the injection of RCS-01 is not only...
Press Release
RepliCel’s Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems
First-in-human clinical study meets primary endpoint demonstrating product safety and clinical potential for tendon regeneration...
Press Release
RepliCel’s Phase 1 Clinical Trial For Hair Loss Succeeds In Meeting Primary Endpoints
Five-year safety data firmly establishes product safety and confirms ongoing clinical and product development strategyVANCOUVER,...
Press Release
RepliCel Pursues Non-Diluting Grant Funding to Accelerate Value Creation and Commercialization
VANCOUVER, BC – March 7, 2017 – RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel”...
Press Release
RepliCel Life Sciences Announces Re-pricing of Warrants
VANCOUVER, BC – March 6, 2017 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)...
Press Release
RepliCel Signs Two Key Service Partnerships for Final Prototype Manufacturing and Testing of its Dermal Injector
VANCOUVER, BC – February 28, 2017 – RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel”...
Press Release
RepliCel Life Sciences Announces Closing of Brokered and Non-brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...
Press Release
RepliCel Announces European Patents for its Innovative Dermal Injector Technologies
RCI-02, RepliCel’s nearest-term commercial asset, enables game-changing reliability, reproducibility, and programmability of three-dimensional skin injections...
Press Release
Replicel Life Sciences Inc. Announces Brokered Private Placement
VANCOUVER, BC – February 7, 2017 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)...
As Seen In
Podcast: Replicel Life Sciences CEO Lee Buckler on global expansion
To listen to Podcast and View Transcript on Financial Post click here
Press Release
RepliCel Appoints Corporate Executive, Hugh Rogers to its Board of Directors
VANCOUVER, BC – February 3, 2017 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP)...
As Seen In
Companies Flocking to Japan for Biotech Deals
To read the full article as it appears on The Life Sciences Report, click here....
As Seen In
ESPN with Bill Daughtry
Listen: http://www.espn.com/espnradio/newyork/play?id=18570324 (at the 1:38 mark)
As Seen In
RepliCel (RP.V) Should Benefit from Renewed Investor Focus, Sweeping Legislation on Cell Therapy
View Article on Zacks Small Cap Research click here
As Seen In
Will 2017 be the year of Cell Therapies?
To read the full article as it appears on The Huffington Post, click here. (1/20/17)While...
As Seen In
Emerging Biotech Companies at Cantech 2017
ProMIS Neurosciences, RepliCel Life Sciences, and Critical Outcome Technologies take the stageView Article by Pia...
As Seen In
RepliCel – Using Cells for Healing
View featured company Article on Advisor Access click here
As Seen In
RepliCel CEO Lee Buckler talks to Cantech Letter
View Article by Nick Waddell on Cantech Letter click here (1/11/2017)...

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.